GENE ONLINE|News &
Opinion
Blog

Hypercholesterolemia
Trials & Approvals Hypercholesterolemia
FDA Extends Approval Of Regeneron’s Evkeeza For Inherited High Cholesterol
2023-03-23
Trials & Approvals Hypercholesterolemia
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
Trials & Approvals CRISPR
Verve Starts Human Trials for Gene Editing Medicine, Targeting Heterozygous Familial Hypercholesterolemia
2022-07-19
Funding Gene Therapy
Looking to Overcome Limitations in Gene Therapy Space, PBM Capital Backed Startup Launches with $20 M in Series A
2021-03-02
Funding Cholesterol
Verve Raises $94M in Series B, Aims to Disrupt Cardiology Market with ‘Once-and-Done’ Gene Editing Therapies
2021-01-21
Deals Cholesterol
AstraZeneca Sells its Cholesterol Drug to German Pharma
2020-12-03
LATEST
Regeneron Steps In to Rescue 23andMe From Bankruptcy With $256M Acquisition
2025-05-20
Virtual trial shows combo rescue inhaler nearly halves severe asthma attacks
2025-05-20
Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition
2025-05-19
The Fight Against Hard-to-Treat Cancers : Bold Bets on a Multifaceted Approach
2025-05-19
CRISPR Makes History with First One-of-a-Kind Gene Therapy for Infant
2025-05-19
VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025
2025-05-15
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
READ MORE
EVENT
2025-05-26
2025 Antibody Therapeutic & Frontiers in Biomedical Sciences Conference
Taipei, Taiwan
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2025 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top